AVENTURA, Fla. and NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic off-the-shelf gene-edited iNK (NK cells derived from iPSC) and CAR (Chimeric Antigen Receptor) Natural Killer (NK) cells derived from induced pluripotent stem cells (iPSCs) and Flex-NK cell engager multifunctional antibodies, and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage gene-editing company employing its core technology to develop products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor (CAR-)T cells in the field of immuno-oncology and gene-edited hematopoietic stem cells in other indications, announced today that they have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells to include new CAR target and development in China by Cytovias joint venture entity, CytoLynx Therapeutics.
The amended financial terms include an equity stake totaling $20 million in Cytovia stock as well as up to $805 million of development, regulatory, and sales milestones and single-digit royalty payments on the net sales of all partnered products commercialized by Cytovia.
We are pleased to expand the collaboration with Cellectis to enable Cytovia to develop iNK products that will leverage the high-precision of TALEN to perform gene-editing to minimize the risk of off-target effects and unlock the full potential of NK cells as a first line of defense against cancer. Cytovias internal research and development, and manufacturing teams are actively developing multiple gene-edited therapeutic candidates and optimizing our technology platform towards next generation products, said Dr. Daniel Teper, Chairman & CEO of Cytovia Therapeutics.
Cellectis is developing custom TALEN, which Cytovia uses to edit iPSCs. Cytovia is responsible for the differentiation and expansion of the gene-edited iPSC master cell bank into NK cells and is conducting the pre-clinical evaluation, clinical development, and commercialization of the mutually-agreed-upon selected therapeutic candidates. Cellectis is granting Cytovia a worldwide license under the patent rights over which Cellectis has the control in this field,including in China, enabling Cytovia to modify NK cells to address multiple gene-targets for therapeutic use in several cancer indications.
We are thrilled at the progress Cytovia has accomplished in the past year, said Dr. Andr Choulika, CEO of Cellectis. Cytovia has attracted a world-class scientific team and is advancing its clinical candidates in areas of significant unmet medical need, sharing Cellectis mission to provide life-saving off-the-shelf allogeneic cell therapy to patients.
About Cytovia Therapeutics Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer.
Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive NK-cell and NK-engager antibody platforms. It is developing three types of iPSC-derived (or iNK) cells: unedited iNK cells, TALEN gene-edited iNK cells with improved function and persistence, and TALEN gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using its proprietary Flex-NK technology.
These two technology platforms are being used to develop treatment of patients with solid tumors such as hepatocellular carcinoma (HCC) and glioblastoma as well as hematological malignancies such as refractory multiple myeloma.
Cytovias research and development laboratories in Natick, MA and GMP cell manufacturing facility in Puerto Rico are augmented by scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, and the University of California San Francisco (UCSF).
Cytovia Therapeutics has recently formedCytoLynxTherapeutics, ajoint-venture entity focused on research and development, manufacturing, and commercialization activities inGreater China and beyond.
Find out more at http://www.cytoviatx.com
About Cellectis Cellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to achieve therapeutic gene editing in hemopoietic stem cells for various genetic disorders. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing cell therapy product candidates utilizing TALEN, its gene editing technology, andPulseAgile, its pioneering electroporation system in order totreat diseases with unmet medical needs.
As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM)..HEALis a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies andlysosomalstorage diseases.
Cellectis headquarters are in Paris, France, with locations in New York City, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
For more information, visit http://www.cellectis.com Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.
For further information on Cellectis, please contact:
Media contacts: Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300 Pascalyne Wilson,Director,Communications,+33776991433, media@cellectis.com
Investor relation contact: EricDutang, Chief Financial Officer,+1 (646) 630 1748, investor@cellectis.com
For further information on Cytovia Therapeutics, please contact:
Investor contact: Anna Baran-Djokovic VP, Investor Relations and Capital Markets anna@cytoviatx.com +1 (305) 615 9162
Media contact: Sophie Badr VP, Corporate Affairs sophie.badre@cytoviatx.com +1 (929) 317-1565
Shani Lewis LaVoieHealthScience slewis@lavoiehealthscience.com +1 (609) 516-5761
Forward-looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as at this time, anticipate, believe, expect, on track, plan, scheduled, and will, or the negative of these and similar expressions. These forward-looking statements, which are based on our managements current expectations and assumptions and on information currently available to management, include statements about our research and development projects and priorities, our pre-clinical project development efforts and the timing of our presentation of data. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development as well as the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2020 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
Attachments
Original post:
Cytovia and Cellectis Expand Their TALEN Gene-Edited iNK Partnership to Enable Broader ... - The Bakersfield Californian
- Israeli-Based 3D-Printed Lab-Grown Meat Company is Building World's ... - December 27th, 2022
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 13th, 2022
- Global Synthetic Stem Cells Market Is Expected To Reach Around USD 42 Million By 2025 - openPR - October 13th, 2022
- A Look Into the Next Century After 100 Years of Insulin - Cureus - October 13th, 2022
- Grafting and Budding Nursery Crop Plants - North Carolina State University - October 4th, 2022
- Lifting up NC Teachers of the Year and TFA alumni - EdNC - August 22nd, 2022
- Vegan Oysters in Shells? This Startup Just Developed a Prototype to Save the Oceans - VegNews - July 27th, 2022
- How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression, anxiety and more - KYMA - July 19th, 2022
- Inceptor Bio Announces Strategic Collaboration with University of Minnesota to Develop Novel iPSC Platform for the Advancement of Next-Generation... - July 3rd, 2022
- W-S organization working on regenerative therapies for 40 organs, tissues - WRAL TechWire - July 3rd, 2022
- BioRestorative Therapies Annou - GuruFocus.com - July 3rd, 2022
- How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression, anxiety - WYFF4 Greenville - June 13th, 2022
- Pediatric Urologist Dr. Anthony Atala to Receive 2022 Jacobson Innovation Award of the American College of Surgeons for Pioneering Work in... - June 13th, 2022
- The Soybean Plant | NC State Extension Publications - June 4th, 2022
- A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked. - June 4th, 2022
- Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting - Yahoo... - April 6th, 2022
- Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT - Yahoo Finance - November 22nd, 2021
- Study Underway to Evaluate New PD-1/CD3 Antibody in T-cell Lymphoma - Targeted Oncology - October 28th, 2021
- What it means to be the worlds first IVF baby - THE WEEK - August 31st, 2021
- Cellectis Announces Participation in Five Investor Conferences - Yahoo Finance - August 31st, 2021
- Nanodecoy Therapy is an Effective Alternative to Neutralize SARS-CoV-2 Virus - AZoNano - June 23rd, 2021
- 'Nanodecoy' Therapy Binds and Neutralizes SARS-CoV-2 Virus - NC State News - June 23rd, 2021
- Researchers curb local immune response in horses receiving stem cell injury therapy - Horsetalk - February 7th, 2021
- After Bone Marrow Donation Saves 9-Year-Old Boy With Cancer, Boston Mom Fights To Raise Awareness - Here And Now - February 7th, 2021
- Invisible pest causes more than $1 billion in crop losses - The Albany Herald - January 13th, 2021
- Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 billion - Reuters - January 13th, 2021
- Chancellor Harold L. Martin, on His Plan to Safely Open the Nation's Largest HCBU During COVID-19 - TIME - August 23rd, 2020
- Inside the race to ditch formula and grow breast milk in the lab - Wired.co.uk - August 23rd, 2020
- Study finds little evidence to back cord-blood therapy for autism - Spectrum - June 12th, 2020
- Balding men could grow hair back in weeks thanks to 'miracle potion' - Daily Star - May 19th, 2020
- Treatment in clinical trial offers options to woman fighting return of cancer (+ video) - WRAL Tech Wire - February 28th, 2020
- Searching for the 'big break' that could turn stem cells into a weapon against dementia - Genetic Literacy Project - February 28th, 2020
- Why Some COVID-19 Cases Are Worse than Others - The Scientist - February 28th, 2020
- The Future of Bioprinting Research Has a New Road Map - 3DPrint.com - February 14th, 2020
- Top Florida Medical Spa, Amnion of Florida, Partners With Merakris Therapeutics to Advance Their Non-Surgical Treatment Options - Business Wire - December 11th, 2019
- Synthetic Stem Cells Market Is Expecting Revolutionary Growth 2019 with Top Key Players: North Carolina State University (NCSU), Zhengzhou University... - December 6th, 2019
- Clinic pitches unproven treatments to desperate patients, with tips on raising the cash - Seattle Times - December 6th, 2019
- Reviewing vTv Therapeutics Inc. (VTVT)'s and Asterias Biotherapeutics Inc. (:)'s results - MS Wkly - October 27th, 2019
- Reviewing BioCryst Pharmaceuticals Inc. (BCRX)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 27th, 2019
- Global Synthetic Stem Cells Market Estimated to Reach USD 42 Million By 2025 - Daily Market Updates - September 29th, 2019
- Global Synthetic Stem Cells Market to Accumulate Revenues Worth US $42 Million By 2025 - ZMR News Research - September 24th, 2019
- Heal Yourself: How Exosome Therapy Can Repair Age-Damaged Skin - Market Research Finance - September 24th, 2019
- Cesca Therapeutics Inc. (KOOL) Can't Be More Safe. Trades Significantly Higher - Invest Tribune - September 24th, 2019
- Stem Cell Winston Salem North Carolina 27150 - April 5th, 2019
- Clinical Trial for Autism - cordbloodbank.com - March 8th, 2019
- Stem Cell Chapel Hill North Carolina 27514 - February 11th, 2019
- Alumna to compete for Miss America crown on Sunday - UNCSA - February 3rd, 2019
- Stem Cell Therapy Latest Research Charlotte, North Carolina - December 2nd, 2018
- Stem Cell Therapy North Carolina | Regenerative Medicine ... - October 4th, 2018
- Bone Marrow Transplant | Durham, Raleigh, North Carolina ... - July 24th, 2018
- Charlotte, North Carolina - Stem Cells Transplant Institute - July 15th, 2018
- Stem Cell Greensboro North Carolina 27455 - July 15th, 2018
- Spotlights Archive | The University of North Carolina at ... - October 15th, 2017
- Stem Cells in Focus - Blog - Closer Look at Stem Cells - October 10th, 2017
- Avalon Advisors Has Decreased Its Comcast Cmn Class (CMCSA) Position; Neuralstem (CUR)'s Sentiment Is 0 - High Point Observer - September 6th, 2017
- Former basketball star Greg Friel in fight of his life - Fosters - Foster's Daily Democrat - August 15th, 2017
- Lung fibrosis? Stem cell therapy holds promise - The Hindu - The Hindu - August 11th, 2017
- Stem cells may treat lung fibrosis diseases - Futurity: Research News - August 11th, 2017
- CRISPR Edits Genome of Human Embryos - Alzforum - August 11th, 2017
- Cary NC Stem Cell Treatment | Cary North Carolina Cancer ... - November 16th, 2016
- Cato - Research Triangle Park, Durham, North Carolina - August 21st, 2016
- Biotechnology Teacher Resources Online | North Carolina ... - August 19th, 2016
- Stem Cell Research in North Carolina ... Whats Really ... - August 5th, 2016
- JCI - Type 2 alveolar cells are stem cells in adult lung - October 19th, 2015
- Cary North Carolina Stem Cell Research | Cary NC Stem Cell ... - July 2nd, 2015
- Core labs | North Carolina Biotech Center - April 29th, 2015
- Image: Human endothelial cells experiment bound for ISS - February 26th, 2015
- COPD Prognosis Stem Cells Canada, COPD Alternative ... - February 17th, 2015
- Cancer Care Northwest Stem Cell Transplantation - January 10th, 2015
- Dying child approved for new treatment testing - January 2nd, 2015
- New e-Incubator enables real-time imaging of bioengineered tissues in controlled unit - November 5th, 2014
- Committee on Development, Regeneration, and Stem Cell ... - October 31st, 2014
- Local doctor uses stem cells to heal - October 29th, 2014
- Study Offers Fertility Preservation Option to Young Boys with Cancer - October 1st, 2014
- Fayetteville North Carolina Stem Cell Research ... - September 16th, 2014
- Charlotte NC Resources - Stem Cells: Get Facts on Uses ... - September 1st, 2014
- For the first time, researchers isolate adult stem cells ... - August 26th, 2014
- The Man Who Grew Eyes From Scratch - August 26th, 2014
- Carolina Stem Cell Treatment Center | carolina stem ... - August 22nd, 2014
- North Carolina Stem Cell Treatment | Stem Cell Treatments - August 22nd, 2014